Innovative Pharmaceutical Biotech (HKSE:00399) Change In Receivables : HK$0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Innovative Pharmaceutical Biotech Change In Receivables?

Innovative Pharmaceutical Biotech's change in receivables for the quarter that ended in Sep. 2024 was HK$0.00 Mil. It means Innovative Pharmaceutical Biotech's Accounts Receivable stayed the same from Mar. 2024 to Sep. 2024 .

Innovative Pharmaceutical Biotech's change in receivables for the fiscal year that ended in Mar. 2024 was HK$1.33 Mil. It means Innovative Pharmaceutical Biotech's Accounts Receivable declined by HK$1.33 Mil from Mar. 2023 to Mar. 2024 .

Innovative Pharmaceutical Biotech's Accounts Receivable for the quarter that ended in Sep. 2024 was HK$3.37 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Innovative Pharmaceutical Biotech's Days Sales Outstanding for the six months ended in Sep. 2024 was 203.17.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Innovative Pharmaceutical Biotech's liquidation value for the six months ended in Sep. 2024 was HK$-904.66 Mil.

Innovative Pharmaceutical Biotech Change In Receivables Historical Data

The historical data trend for Innovative Pharmaceutical Biotech's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innovative Pharmaceutical Biotech Change In Receivables Chart

Innovative Pharmaceutical Biotech Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Change In Receivables

Get a 7-Day Free Trial

5.34

0.21

6.14

3.27

1.33

Innovative Pharmaceutical Biotech Semi-Annual Data
	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24
Change In Receivables	Get a 7-Day Free Trial															-	-	-	-	-

Innovative Pharmaceutical Biotech Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.00 Mil.

Innovative Pharmaceutical Biotech (HKSE:00399) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Innovative Pharmaceutical Biotech's Days Sales Outstanding for the quarter that ended in Sep. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	3.372	/	3.029	*	91
=	203.17

2. In Ben Graham's calculation of liquidation value, Innovative Pharmaceutical Biotech's accounts receivable are only considered to be worth 75% of book value:

Innovative Pharmaceutical Biotech's liquidation value for the quarter that ended in Sep. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	0.428	-	907.618	+	0.75 * 3.372	+	0.5 * 0
=	-904.66

Innovative Pharmaceutical Biotech Change In Receivables Related Terms

Thank you for viewing the detailed overview of Innovative Pharmaceutical Biotech's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Innovative Pharmaceutical Biotech Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Cyclical » Retail - Cyclical » Innovative Pharmaceutical Biotech Ltd (HKSE:00399) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

145 Hennessy Road, Unit No. 2002, 20th Floor, On Hong Commercial Building, Wan Chai, Hong Kong, HKG

Website

http://www.ipb.asia

Innovative Pharmaceutical Biotech Ltd is a Hong Kong-based investment holding company principally engaged in pharmaceuticals and biotechnology businesses. The company has two operating segments; Trading of beauty products in Hong Kong and Research, development, and commercialisation of the oral insulin product. The company generates almost all of its revenue from Hong Kong.

Executives

Mao Yumin	2101 Beneficial owner
Chau Yiu Ting	2101 Beneficial owner
Extrawell Pharmaceutical Holdings Limited
Mao Yumin	2101 Beneficial owner
Chau Yiu Ting	2101 Beneficial owner

Innovative Pharmaceutical Biotech Headlines

No Headlines